Centers | ||
|
|
|
Edinburgh Drug Discovery | Weccome Centre for Anti-Infectives Research | Therapeutic Accelerator Program (TAP) |
Based within the world-leading University of Edinburgh Medical School, Edinburgh Drug Discovery has a track record in successfully translating drug discovery projects from target identification through to clinical evaluation. Key areas of... |
WCAIR brings together the Drug Discovery Unit (DDU) , the Mode of Action group and the Parasitology research groups. With the daily interactions of these groups, parasitology and drug discovery can work together in synergy. This empowers us to create... Read more |
Test |
Partnerships |
Events |
Jobs |
Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all Argenta and ANTABIO Announce Drug Discovery CollaborationArgenta, a Galapagos NV (Euronext: GLPG) company that provides drug discovery services from target validation to proof of concept, announced today that it has achieved a milestone with its collaboration partner Antabio in an anti-bacterial drug... View all Brigham & Woman's Hospital and Sanofi to Partner in Type 1 Diabetes SpaceSanofi and Brigham & Woman's Hospital an affiliate of Harvard University have entered into a joint collaboration to develop new drugs based on novel immunomodulatory approach to treat Type 1 Diabetes. Scientists from both groups will be... View all |
No EVENTS for listing |
No Job Posts |
